<DOC>
	<DOC>NCT02266173</DOC>
	<brief_summary>This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 3000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in Korea. Participants who are administered with pertuzumab according to medical opinions of the doctor in charge of surveillance will be registered for this study and treated with pertuzumab under the approval conditions of the product in Korea.</brief_summary>
	<brief_title>Observational Study of Pertuzumab Safety in Participants With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or antiHER2 therapy for metastatic disease with HER2 positivity HER2positive, locally advanced, inflammatory, or early stage breast cancer (greater than [&gt;]2 centimeters [cm] in diameter) participants who have never received chemotherapy and surgery for breast cancer Hypersensitivity for pertuzumab (Perjeta) or any of its excipients Contraindications to Perjeta according to SmPC Pregnancy and lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>